{
  "id": 20933196,
  "title": "JPMorgan’s Names Top Biotech Stocks",
  "url": "https://urgent.news/2026/11/20/jpmorgans-names-top-biotech-stocks",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-20T18:28:44.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/stock-market-news/jpmorgans-names-top-biotech-stocks-5042393"
  },
  "original_language": "en",
  "account": "JPMorgan has released its latest rankings of top biotechnology stocks, focusing on companies operating in the rare disease and oncology sectors. The investment bank's selections include both commercially successful companies and those in the clinical development stage, with price targets indicating substantial upside potential from their current market prices. The rankings take into account factors such as commercial execution, pipeline potential, and strategic value in the context of an active mergers and acquisitions market.\n\nRhythm Pharmaceuticals (RYTM) leads the rankings with an Overweight rating and a $142 price target for 2027. Currently trading at $119 per share, the company boasts a $8.3 billion market capitalization and has increased by 13% year-to-date. Rhythm Pharmaceuticals commercializes Imcivree, a treatment for rare genetic obesity conditions. The company has received over 700 patient sign-up forms for the Acquired Hypothalamic Obesity indication, with strong early persistence. Analysts note that the current valuation does not fully account for the potential of the Prader-Willi Syndrome opportunity, which has attracted a reported $10 billion acquisition offer from AstraZeneca. JPMorgan projects that the company's adjusted sales could reach a peak of $2.7 billion.\n\nRelay Therapeutics (RLAY) also receives an Overweight rating, with a $31 price target. The oncology company is developing zovegalisib, a PI3Ka inhibitor for breast cancer and vascular anomalies. Physician checks indicate that roughly 60-70% of patients with PI3Ka-mutant second-line-plus breast cancer could be prescribed zovegalisib. Phase 1/2 data has shown a 11.1-month progression-free survival rate and a 43% objective response rate. JPMorgan's analysis highlights the potential for a $5 billion-plus total addressable market in the vascular anomalies opportunity, with significant potential for success.",
  "summary": null,
  "key_points": [
    "JPMorgan ranks Rhythm Pharmaceuticals (RYTM) top biotech stock with $142 price target",
    "RLYA receives Overweight rating with $31 price target for oncology development",
    "Rhythm's Imcivree treatment for rare obesity conditions generates significant patient interest"
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}